How Has The Viral Vector Manufacturing Market Size Evolved Historically?
The viral vector manufacturing market has seen considerable growth due to a variety of factors.
•The size of the viral vector manufacturing market has seen significant expansion in the past few years. The market value is projected to grow from $6.93 billion in 2024 to $8.33 billion in 2025, indicating a compound annual growth rate (CAGR) of 20.1%.
Factors such as the growth in gene therapy pipelines, successful clinical trials and approvals, higher investment in biopharmaceuticals, and a rise in genetic disorders can all be linked to the growth during the historical period.
What Will Be The Viral Vector Manufacturing Market Size In The Future?
The viral vector manufacturing market is expected to maintain its strong growth trajectory in upcoming years.
• The market size for viral vector manufacturing is forecasted to witness significant expansion in the forthcoming years. It is estimated to reach a whopping $17.68 billion by 2029 with a CAGR of 20.7%.
Several factors are contributing to this growth during the forecast period, including the increasing uses in oncology, worldwide partnerships in the field of gene therapy research, the use of viral vectors in the creation of vaccines, ongoing clinical trials, and commercialization. Upcoming trends for the forecast period consist of advances in vector production technology, the rise of next-generation vectors, compliance with regulations and standardization, collaborative efforts and partnerships, and the worldwide growth of manufacturing facilities.
What Are The Key Drivers Fueling Growth In The Viral Vector Manufacturing Market?
The rise in commonness of cancer and infectious diseases are anticipated to drive the growth of the viral vector manufacturing market in the future. Infectious diseases are conditions resulting from a virus or its harmful byproduct, spreading from an infected person, animal, or object to a susceptible host. Cancer, on the other hand, is a diverse set of diseases that occur when abnormal cells multiply uncontrollably, exceed their typical boundaries to invade nearby organs, and metastasize to other organs. The body's anticancer immunological response is activated by tumor antigens or proteins on tumor cells, which are generated through viral vectors. Viral vectors have been used in pre-clinical and clinical studies as vaccines against various infectious diseases. For example, the Australian Institute of Health and Welfare, a government agency based in Australia, reported in July 2024, that the number of diagnosed cancer cases in Australia increased from 160,570 in 2022 to 164,694 in 2023, demonstrating a significant year-on-year increase. This rising trend underlines the increasing incidence of cancer in the country. Moreover, data from the UK-based executive agency, the UK Health Security Agency, as of August 2024, showed that England had 368 measles cases in 2023, approximately seven times the 53 cases reported in 2022. The West Midlands and London represented 44% and 33% of these cases, respectively. Hence, the rise in the incidence of cancer and infectious diseases is fuelling the expansion of the viral vector manufacturing market.
What Are The Principal Market Segments In The Global Viral Vector Manufacturing Industry?
The viral vector manufacturing market covered in this report is segmented –
1) By Type: Adenoviral Vectors, Adeno-Associated Viral Vectors, Lentiviral Vectors, Retroviral Vectors, Other Types
2) By Disease: Cancer, Genetic Disorders, Infectious Diseases, Other Diseases
3) By Workflow: Upstream Processing, Downstream Processing
4) By Application: Gene And Cell Therapy Development, Vaccine Development, Biopharmaceutical And Pharmaceutical Discovery, Biomedical Research
5) By End-User: Research Organizations, Biotech And Pharmaceutical Companies, Others End Users
Subsegments:
1) By Adenoviral Vectors: Serotype 5, Serotype 2, Serotype 26
2) By Adeno-Associated Viral Vectors: AAV2, AAV5, AAV8, AAV9, Others
3) By Lentiviral Vectors: HIV-1-Based Lentiviral Vectors, SIV-Based Lentiviral Vectors, Others
4) By Retroviral Vectors: Moloney Murine Leukemia Virus (MoMLV), Gammaretroviral Vectors, Others
5) By Other Types: Sendai Viral Vectors, Vesicular Stomatitis Virus (VSV)-Based Vectors, Measles Virus Vectors, Others
Pre-Book The Viral Vector Manufacturing Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
Which Emerging Market Trends Are Altering The Viral Vector Manufacturing Sector?
Embracing product innovation is on the rise as a crucial trend in the viral vector manufacturing market. Prime businesses in this market are launching innovative products to maintain their market standing. Take, for example, Merck KGaA, a German science and technology company that unveiled the VirusExpress 293 Adeno-Associated Virus (AAV) Production Platform in August 2022. It stands as one of the first Contract Development and Manufacturing Organizations and technology pioneers to provide a comprehensive viral vector manufacturing solution, including AAV, Lentiviral, CDMO, CTO, and process development. This platform enables biopharmaceutical companies to cut down on process development costs and time, consequently expediting their journey to clinical production.
Who Are the Key Players in the Viral Vector Manufacturing Market?
Major companies operating in the viral vector manufacturing market include:
• Sanofi S.A.
• Thermo Fisher Scientific Inc.
• Merck Group
• FUJIFILM Holdings Corporation
• Lonza Group
• Catalent Inc.
• Sartorius AG
• Charles River Laboratories International Inc.
• AGC Biologics
• Ultragenyx Pharmaceutical Inc.
• Novasep Holding SAS
• Aldevron LLC
• Oxford Biomedica plc
• LakePharma Inc.
• Voyager Therapeutics Inc.
• Mustang Bio Inc.
• Regenxbio Inc.
• VGXI Inc.
• BioNTech IMFS GmbH
• FinVector Oy
• Vigene Biosciences Inc.
• Univercells Technologies
• Sirion-Biotech GmbH
• Cevec Pharmaceuticals GmbH
• Batavia Biosciences BV.
What are the Regional Insights into the Viral Vector Manufacturing Market?
North America was the largest region in the viral vector manufacturing market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the viral vector manufacturing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
